Skip to content

Prospective Randomized, Controlled Trial for Treatment of Intraventricular Hemorrhage

A Prospective Randomized, Controlled Trial for Treatment of Intraventricular Hemorrhage: External Ventricular Drainage and Intraventricular Thrombolysis vs. External Ventricular Drainage and Endoscopic Evacuation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01064011
Acronym
IVH
Enrollment
34
Registered
2010-02-08
Start date
2010-01-31
Completion date
2014-01-31
Last updated
2011-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraventricular Hemorrhage

Brief summary

Intraventricular hemorrhage comprises about 15% of the 500,000 strokes that occur annually in the United States. In the emergent setting, patients with obstructive hydrocephalus are routinely treated with placement of an external ventricular drain. This study will compare the effect of external ventricular drainage plus intraventricular thrombolysis versus external ventricular drainage plus endoscopic evacuation on neurologic outcomes for patients with hydrocephalus from intraventricular hemorrhage.

Interventions

PROCEDURERt-PA thrombolysis

patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.

PROCEDUREendoscopic hematoma evacuation

In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.

Sponsors

Albany Medical College
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-75 * Radiographic evidence of intraventricular hemorrhage with hydrocephalus * Admission Glasgow Coma Scale ≥ 5 (motor score ≥ 2) * Placement of an external ventricular drain with an opening pressure \>20 mm Hg

Exclusion criteria

* Intraventricular hemorrhage secondary to cerebral aneurysm, arteriovenous malformation, or tumor * Coagulopathy (Platelet count \<100,000, International normalized ratio \>1.5. Reversal of warfarin is permitted.) * Age \<18 or \>75 * Pregnancy (positive pregnancy test) * Clotting disorders * Medical contraindications to administration of general anesthesia as determined by the attending anesthesiologist * Medical contraindications to surgery as determined by the attending neurosurgeon * Contraindication to recombinant tissue plasminogen activator administration: * Evidence of enlargening intracranial hemorrhage as evidenced by an increase in intracranial hemorrhage volume (\>5 ml) on CT obtained after EVD placement * Internal bleeding, involving retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts * Superficial or surface bleeding, observed at vascular puncture and access sites (e.g. venous cutdowns, arterial punctures) or site of recent surgical intervention * Evidence of cerebrospinal infection by Gram stain or culture * Advanced directive indicating Do Not Resuscitate or Do Not Intubate status

Countries

United States

Contacts

Primary ContactYu-Hung Kuo, MD
kuoy@mail.amc.edu518 262-5088
Backup ContactTyler Kenning, MD
kennint@mail.amc.edu518 262-5088

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026